Journal
LIVER INTERNATIONAL
Volume 41, Issue 11, Pages 2560-2577Publisher
WILEY
DOI: 10.1111/liv.15061
Keywords
COVID-19; liver function tests; immune response; MAFLD
Categories
Ask authors/readers for more resources
Metabolic diseases are linked to a higher risk of severe COVID-19, with fatty liver exacerbating hepatic inflammation in the presence of SARS-CoV-2 infection. Intestinal dysbiosis serves as a powerful activator of liver macrophage inflammatory response, playing a key role in MAFLD progression towards liver fibrosis.
Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID-19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low-grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non-alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID-19 can have a worse outcome of COVID-19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID-19 complexity and to improve knowledge on its pathophysiology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available